Fulgent Genetics (FLGT) EBITDA Margin (2015 - 2026)
Fulgent Genetics (FLGT) posted EBITDA Margin of 42.25% for Q2 2026, up 13.2% sequentially from 48.67% in Q1 2026, and down 1815.0% YoY from 2.46% in Q2 2025.
Fulgent Genetics (FLGT) EBITDA Margin (2015 - 2026) Analysis & Trends
Fulgent Genetics has reported EBITDA Margin for 12 years, with the latest figure at 42.25% in Q2 2026.
- Quarterly EBITDA Margin fell 1815.0% year-over-year to 42.25% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 35.91% (down 1193.0% YoY) and the FY2025 annual result came in at 28.23%, down 216.0% from the prior year.
- EBITDA Margin rose to 42.25% in Q2 2026 per FLGT's latest filing, from 48.67% in the prior quarter.
- Over five years, EBITDA Margin peaked at 63.05% in Q1 2022 and troughed at 214.34% in Q4 2023.
- A 5-year average of 32.08% and a median of 25.36% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin sank 23468 bps in 2023, then soared 19317 bps in 2024.
- Over 5 years, EBITDA Margin stood at 20.33% in 2022, then tumbled by 1154 bps to 214.34% in 2023, then jumped by 90 bps to 21.17% in 2024, then slumped by 490 bps to 125.0% in 2025, then jumped by 66 bps to 42.25% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 42.25%, 48.67%, and 125.0% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 17.40% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 17.99% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 34.98% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 21.74% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 11.58% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -13.42% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 21.14% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 31.97% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 15.08% |
| 10 | Fulgent Genetics | 518.37 Mn | 261.34 Mn | 25.68 Mn | -42.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -42.25% |
| Mar 31, 2026 | -48.67% |
| Dec 31, 2025 | -125.00% |
| Sep 30, 2025 | -18.26% |
| Jun 30, 2025 | -24.10% |
| Mar 31, 2025 | -26.95% |
| Dec 31, 2024 | -21.17% |
| Sep 30, 2024 | -23.81% |
| Jun 30, 2024 | -26.62% |
| Mar 31, 2024 | -33.80% |
| Dec 31, 2023 | -214.34% |
| Sep 30, 2023 | 0.25% |
| Jun 30, 2023 | -29.18% |
| Mar 31, 2023 | -37.52% |
| Dec 31, 2022 | 20.33% |
| Sep 30, 2022 | 0.33% |
| Jun 30, 2022 | 10.21% |
| Mar 31, 2022 | 63.05% |
| Dec 31, 2021 | 59.94% |
| Sep 30, 2021 | 69.90% |